SAN CARLOS, Calif.,
Sept. 2, 2014 /PRNewswire/
-- Intrexon Corporation (NYSE: XON), a leader in synthetic
biology, today announced that it has entered into an Exclusive
Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned
subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an
enhanced production process for a specific family of its marketed
Active Pharmaceutical Ingredients (APIs) through Sanofi's current
manufacturing operations in France. This collaboration will leverage
Intrexon's proprietary technology suite plus Sanofi's expertise and
innovation in yeast metabolism and industrial chemistry to increase
overall yield.
Under the ECC, Intrexon will utilize its advanced computational
biology and bioinformatics to identify the most efficient
biological pathways for producing these marketed APIs.
Intrexon's Industrial Product Division facilities in Hungary and California will design and synthesize new
components tailored to drive optimal output from constructed cell
lines leading to improved process economics. Furthermore, for
faster, more efficient collaboration, Intrexon intends to provide
ECC partners like Sanofi the ability to remotely access its
extensive library of characterized genetic components facilitating
customized gene design and high-throughput modular DNA assembly via
its new BeyondBio™ platform.
"We are excited to partner with Sanofi to improve existing
fermentation processes, providing a competitive advantage in
marketed APIs production," said Randal J.
Kirk, Intrexon Chairman and Chief Executive Officer. "We are
confident that our synthetic biology expertise and robust
technology platforms will drive development of Sanofi's
next-generation strain in a commercially feasible way that also
produces the highest possible yields."
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic
biology focused on collaborating with companies in Health,
Consumer, Food, Energy, and Environment Sectors to create
biologically-based products that improve the quality of life and
the health of the planet. Through the company's proprietary
UltraVector® platform and suite of technologies, Intrexon provides
its partners with industrial-scale design and development of
complex biological systems. The UltraVector® platform
delivers unprecedented control over the quality, function, and
performance of living cells. We call our synthetic biology
approach and integrated technologies Better DNA®, and we invite you
to discover more at www.DNA.com.
Trademarks
Intrexon, BeyondBio, UltraVector, and Better DNA are trademarks
of Intrexon and/or its affiliates. Other names may be
trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are
forward-looking statements. These forward-looking statements
are based upon our current expectations and projections about
future events and generally relate to our plans, objectives and
expectations for the development of our business. Although
management believes that the plans and objectives reflected in or
suggested by these forward-looking statements are reasonable, all
forward-looking statements involve risks and uncertainties and
actual future results may be materially different from the plans,
objectives and expectations expressed in this press release.
For more information contact:
Intrexon Corporation Contacts:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
Investors@intrexon.com
SOURCE Intrexon Corporation